A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia
Key
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Incidence of serious adverse reactions
Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose
Yes
United States: Food and Drug Administration
CLT008-02
NCT01297543
March 2011
Name | Location |
---|---|
University of Massachusetts Memorial Medical Center | Worcester, Massachusetts 01655 |
Moores UCSD Cancer Center | La Jolla, California 92093-0658 |
University of Minnesota | Minneapolis, Minnesota 55455 |
Cleveland Clinic | Cleveland, Ohio 44195 |
The Western Pennsylvania Hospital | Pittsburgh, Pennsylvania 15224 |
Stanford Hospital and Clinics | Stanford, California 94305 |
The University of Texas MD Anderson Cancer Center | Houston, Texas 77030-4009 |
Loyola University Medical Center, Cardinal Bernardin Cancer Center | Maywood, Illinois 60153 |
Case Western Reserve University, University Hospitals of Cleveland | Cleveland, Ohio 44106 |
University of California San Francisco Medical Center | San Francisco, California 94143 |
Indiana Blood and Marrow Transplantation, LLC | Beech Grove, Indiana 46107 |